Effectiveness of Transcatheter arterial micro-emblization for nighttime shoulder pain : Multicenter Study

Effectiveness of Transcatheter arterial micro-emblization for nighttime shoulder pain : Multicenter Study - shoulde TAME : JMIS-1601 (TAME-II)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021238

Enrollment

100

Registered

2016-02-28

Start date

2016-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nighttime shoulder pain refractory to non-surgical management

Interventions

Transcatheter arterial micro embolization: TAME

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Previous conservative therapies applied for at least 3 months and persistent moderate-to-severe pain (VAS > 50mm). 2.Patients with following diagnosis: adhesive capsulitis, Inoperable rotator cuff injury 3. Patients who maintain major organ (bone marrow, heart, liver, lung, kidney) function. 4. Provided written informed consent to undergo the procedure.

Exclusion criteria

Exclusion criteria: 1.Reheumatoid arthritis 2.Neoplasm 3.Severe arteriosclerosis 4.Pregnant female 5.Dementia 6.Complaining joint instability 7.Iodine Allergy 8.Patients with severe cardiac disease, cerebrovascular disease, neurological disease, uncontrollable diabetic mellitus and hypertension, severe infection, intestinal bleeding, interstitial pneumonia, ascites fluid, pleural effusion. 9, Pain due to cervical or lumbar spine pathology 10,Patients who was decided not to be appropriate for this trial by physician

Design outcomes

Primary

Measure	Time frame
Numerical Rating Scale (NRS) in 6 months after procedure range of motion (ROM) in 6 months after procedure Quality of Life(QOL) in 6 months after procedure	—

Countries

Japan

Contacts

Public ContactAtsushi Komemushi

Kansai Medical University Radiology

tame.trial@gmail.com06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026